Request Trial
L-R: Samuel Jinks, David Degen, Kritika Chhokra, Carola Lempke
14 November 2025NewsEuropeMarisa Woutersen

Too busy to save time? Why IP teams can’t afford to wait on AI

In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Emotional Perception: What next for patent holders?
3 March 2026   After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.
Europe
Emotional Perception exclusive: ‘We are now very much open for business’
16 February 2026   Following the UK Supreme Court’s recent landmark judgment, which ushers in a sea-change to patent law, the team behind a groundbreaking AI-related invention sit down with Sarah Speight to explain how they got here, and why the ruling changes everything.
Europe
UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents
12 February 2026   The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

Mylan withdraws defence claims against Novo in Wegovy dispute
INTA: ‘New normal’ for in-house counsel as budgets fall
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
Astellas blocks generic version of key urology drug until 2030
Orrick adds specialist licensing partner in Silicon Valley
GSK inks licensing deal for liver disease drug
Arnold & Porter adds tech litigator in San Francisco
Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs